Video

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Jyoti Mayadev, MD, professor, assistant vice chair, Developmental Therapeutics, section chief, Gynecologic Oncology, co-leader, GYN Oncology Disease Team, Moores NCI-Designated Comprehensive Cancer Center, UC San Diego School of Medicine, discusses the phase 1 NRG-GY017 trial (NCT03738228) evaluating atezolizumab (Tecentriq) given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

The key takeaway from the trial is that it was safe to combine an anti–PD-L1 agent with chemoradiation, Mayadev says. Few dose-limiting toxicities were observed with this approach in this population, Mayadev adds. Additionally, when examining T-cell clones in the patient's peripheral blood and the tumors, it was found that patients who received chemoradiation had an expansion of T-cell clonality. Notably, new, novel clones were observed, as opposed to tumor-associated clones, Mayadev concludes.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD